Crispr technology may be the key to a range of blockbuster new drugs, but the road ahead could be filled with potholes. Years from now, the Crispr companies that successfully run the drug-discovery gauntlet will need a sales force. The lion's share of a drug's economic value often ends up with the marketer, not the developer. It is common for a drug's marketer to pay a royalty to a drug's developer in the range of 20% or less. Companies that will likely be the marketers of these drugs, such as Eli Lilly, Amgen and Gilead, are good ways to invest in Crispr technology with much less risk.

Source: Forbes May 09, 2019 17:03 UTC